Back to Browse Journals » Vascular Health and Risk Management » Volume 8

Cerebral blood flow in Alzheimer’s disease

Authors Roher AE, Debbins JP, Malek-Ahmadi M, Chen K, Pipe JG, Maze S, Belden C, Maarouf CL, Thiyyagura P, Mo H, Hunter JM, Kokjohn TA, Walker DG, Kruchowsky JC, Belohlavek M, Sabbagh MN, Beach TG

Published Date October 2012 Volume 2012:8 Pages 599—611

DOI http://dx.doi.org/10.2147/VHRM.S34874

Received 9 June 2012, Accepted 14 September 2012, Published 23 October 2012

Alex E Roher,1 Josef P Debbins,2 Michael Malek-Ahmadi,3 Kewei Chen,4 James G Pipe,2 Sharmeen Maze,2 Christine Belden,3 Chera L Maarouf,1 Pradeep Thiyyagura,4 Hua Mo,4 Jesse M Hunter,1 Tyler A Kokjohn,1,5 Douglas G Walker,6 Jane C Kruchowsky,6 Marek Belohlavek,7 Marwan N Sabbagh,3 Thomas G Beach8

1The Longtine Center for Neurodegenerative Biochemistry, Banner Sun Health Research Institute, Sun City, 2Keller Center for Imaging Innovation, Neuroimaging Research, Barrow Neurological Institute, Phoenix, 3Cleo Roberts Center for Clinical Research, Banner Sun Health Research Institute, Sun City, 4Computational Image Analysis Program, Banner Alzheimer’s Institute, Phoenix, 5Department of Microbiology, Midwestern University, Glendale, 6Laboratory of Neuroinflammation, Banner Sun Health Research Institute, Sun City, 7Division of Cardiovascular Diseases, Mayo Clinic, Scottsdale, 8Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ, USA

Background: Alzheimer’s disease (AD) dementia is a consequence of heterogeneous and complex interactions of age-related neurodegeneration and vascular-associated pathologies. Evidence has accumulated that there is increased atherosclerosis/arteriosclerosis of the intracranial arteries in AD and that this may be additive or synergistic with respect to the generation of hypoxia/ischemia and cognitive dysfunction. The effectiveness of pharmacologic therapies and lifestyle modification in reducing cardiovascular disease has prompted a reconsideration of the roles that cardiovascular disease and cerebrovascular function play in the pathogenesis of dementia.
Methods: Using two-dimensional phase-contrast magnetic resonance imaging, we quantified cerebral blood flow within the internal carotid, basilar, and middle cerebral arteries in a group of individuals with mild to moderate AD (n = 8) and compared the results with those from a group of age-matched nondemented control (NDC) subjects (n = 9). Clinical and psychometric testing was performed on all individuals, as well as obtaining their magnetic resonance imaging-based hippocampal volumes.
Results: Our experiments reveal that total cerebral blood flow was 20% lower in the AD group than in the NDC group, and that these values were directly correlated with pulse pressure and cognitive measures. The AD group had a significantly lower pulse pressure (mean AD 48, mean NDC 71; P = 0.0004). A significant group difference was also observed in their hippocampal volumes. Composite z-scores for clinical, psychometric, hippocampal volume, and hemodynamic data differed between the AD and NDC subjects, with values in the former being significantly lower (t = 12.00, df = 1, P = 0.001) than in the latter.
Conclusion: These results indicate an association between brain hypoperfusion and the dementia of AD. Cardiovascular disease combined with brain hypoperfusion may participate in the pathogenesis/pathophysiology of neurodegenerative diseases. Future longitudinal and larger-scale confirmatory investigations measuring multidomain parameters are warranted.

Keywords: Alzheimer’s disease, cerebral blood flow, brain hypoperfusion, two-dimensional phase-contrast magnetic resonance imaging, brain morphometric analyses, atherosclerosis, arteriosclerosis, cognitive impairment

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Congenital anomaly of the inferior vena cava and factor V Leiden mutation predisposing to deep vein thrombosis

Lamparello BM, Erickson CR, Kulthia A, Virparia V, Thet Z

Vascular Health and Risk Management 2014, 10:609-613

Published Date: 4 November 2014

Consumption of water containing over 3.5 mg of dissolved hydrogen could improve vascular endothelial function

Sakai T, Sato B, Hara K, Hara Y, Naritomi Y, Koyanagi S, Hara H, Nagao T, Ishibashi T

Vascular Health and Risk Management 2014, 10:591-597

Published Date: 17 October 2014

Endoglin: a critical mediator of cardiovascular health

Kapur NK, Morine KJ, Letarte M

Vascular Health and Risk Management 2013, 9:195-206

Published Date: 6 May 2013

Dual-channel functional electrical stimulation improvements in speed-based gait classifications

Springer S, Laufer Y, Becher M, Vatine JJ

Clinical Interventions in Aging 2013, 8:271-277

Published Date: 28 February 2013

Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration

Vottonen P, Kaarniranta K, Pääkkönen A, Tarkka IM

Clinical Ophthalmology 2013, 7:437-442

Published Date: 27 February 2013

Current and emerging treatment options for nasopharyngeal carcinoma

Spratt DE, Lee N

OncoTargets and Therapy 2012, 5:297-308

Published Date: 23 October 2012

Rivaroxaban in atrial fibrillation

Giorgi MA, Miguel LS

Vascular Health and Risk Management 2012, 8:525-531

Published Date: 30 August 2012

Bacterial conjunctivitis

Cindy Hutnik, Mohammad H Mohammad-Shahi

Clinical Ophthalmology 2010, 4:1451-1457

Published Date: 6 December 2010

Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease

Raed Osman, Philippe L L’Allier, Nader Elgharib, Jean-Claude Tardif

Vascular Health and Risk Management 2006, 2:221-237

Published Date: 25 January 2006